Tungsten-anisole complex provides 3,6-substituted cyclohexenes for highly diversified chemical libraries

Area of Science:

• Organic Chemistry
• Medicinal Chemistry
• Drug Discovery

Background:

• Current pharmaceutical lead development relies on synthesizing flat molecules using sp2-hybridized atoms.
• These flat molecules often exhibit poor specificity for protein binding sites, hindering drug efficacy.
• Developing novel molecular architectures is crucial for advancing drug discovery.

Purpose of the Study:

• To introduce a new coupling strategy for creating three-dimensional molecules.
• To utilize a cyclohexene linker for connecting diverse molecular fragments.
• To generate novel chemical diversity for pharmaceutical lead development.

Main Methods:

• A tungsten complex was employed to activate anisole.
• The process involved an unusual double protonation of anisole.
• Sequential nucleophilic additions were used to form new sp3 stereocenters.

Main Results:

• A novel coupling strategy was demonstrated, forming two new tetrahedral (sp3) stereocenters.
• This method successfully connected diverse molecular fragments using a cyclohexene linker.
• Both cis- and trans-disubstituted cyclohexenes were prepared with significant chemical diversity.

Conclusions:

• The developed dearomatization method offers a powerful new route to complex, three-dimensional molecules.
• This strategy overcomes the limitations of traditional sp2-based coupling methods in drug discovery.
• The approach provides unparalleled chemical diversity for generating novel pharmaceutical leads.